1 - 3 / 3 1 |
1. Pharmacogenetic markers of adverse events of dopaminergic treatment in Parkinson's disease Sara Redenšek, 2019, doctoral dissertation Keywords: Parkinson's disease, pharmacogenetics, dopaminergic treatment, adverse events, genetic polymorphisms, personalized medicine, clinical-pharmacogenetic models |
2. Treatment response to SGLT2 inhibitors Jasna Klen, Vita Dolžan, 2021, review article Keywords: SGLT2 inhibitors, cardiovascular safety, renal safety, genetic polymorphisms |
3. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity Jasna Klen, Vita Dolžan, 2022, review article Keywords: type 2 diabetes mellitus, obesity, GLP‐1 receptor agonists, incretins, cardiovascular safety, genetic polymorphisms |